Safety Net Provider Drug Pricing Protection Act
- Sponsor
- Rep. Bergman, Jack [R-MI-1]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Oct 29, 2026
Bottom line
The bill ensures immediate 340B drug discounts for specified safety net providers, preventing manufacturers from using rebate models that delay savings and strain provider cash flow.
What it actually does
This bill amends the Public Health Service Act to mandate that certain safety net healthcare providers, participating in the 340B drug pricing program, must receive the discounted 340B ceiling price for covered outpatient drugs at the exact time of purchase. It explicitly prohibits drug manufacturers from requiring these specific providers to pay a higher price upfront and then receive a rebate later, thereby ensuring immediate access to the intended discounts.
Proponents argue
Supporters argue that this legislation is crucial for the financial stability and operational viability of safety net providers, enabling them to better serve vulnerable populations. They contend that requiring upfront discounts aligns with the original intent of the 340B program, improving cash flow for entities like community health centers and rural hospitals, which often operate on thin margins and cannot afford to wait for rebates.
Opponents contend
Critics, particularly some drug manufacturers, may argue that mandating upfront discounts restricts their operational flexibility and could increase administrative burdens. They might contend that rebate models offer necessary business efficiencies or that such mandates could lead to adjustments in drug pricing strategies that ultimately affect other parts of the healthcare system.
The bill is concise and clearly written, making it accessible for a quick and thorough understanding of its provisions.
Section 2(a), amending 42 U.S.C. 256b(a)
Mandatory Upfront 340B Discounted Pricing
This provision adds a new paragraph to the Public Health Service Act, explicitly stating that the Secretary of Health and Human Services cannot enter into agreements with drug manufacturers that allow certain 'safety net covered entities' to pay more than the 340B ceiling price for covered outpatient drugs at the moment of purchase. This means manufacturers cannot require these specific providers to pay the full price and then receive a discount later through a rebate system.
Supporters argue
Proponents argue that this provision directly addresses a critical financial challenge faced by safety net providers, who often struggle with cash flow when forced to wait for rebates. Ensuring upfront discounts allows these providers to immediately reinvest savings into patient care and maintain essential services for underserved communities.
Critics contend
Opponents, primarily drug manufacturers, might argue that this mandate interferes with their commercial practices and could lead to increased administrative complexity. They may prefer the flexibility of rebate models, which can be integrated into broader pricing strategies.
Tradeoffs
The provision balances the financial stability of safety net providers against the operational preferences and business models of pharmaceutical manufacturers. It prioritizes the immediate needs of healthcare providers serving vulnerable populations over manufacturer flexibility in drug pricing and payment terms.
Section 2(b)
Rule of Construction Clarifying Upfront Payment
This subsection explicitly clarifies that no part of the Public Health Service Act, as amended by this bill, should be interpreted to allow any arrangement where a safety net covered entity pays more than the 340B ceiling price at the time of purchase, even if there's a later reconciliation through a rebate or other payment. This reinforces the intent for immediate, upfront discounts.
Defines 'safety net covered entity' by referencing specific subparagraphs of paragraph (4) of section 340B(a) of the Public Health Service Act. These include Federally Qualified Health Centers, certain Disproportionate Share Hospitals, Comprehensive Hemophilia Diagnostic and Treatment Centers, Rural Referral Centers, Sole Community Hospitals, Critical Access Hospitals, Freestanding Cancer Hospitals, Children's Hospitals, and entities receiving direct State/local government funds.
Section 2(a), new paragraph (11)(B)
Why it matters:The use of cross-references is standard legislative practice for brevity and to integrate with existing law, rather than being evasive. However, it requires familiarity with the Public Health Service Act to fully understand which entities are covered.
Case for: The precise definition ensures that the benefits of upfront pricing are targeted to the specific types of safety net providers deemed most in need of this financial support, without broadly altering the 340B program for all participants.
Case against: Some might argue that limiting the scope to these specific entities creates an uneven playing field within the broader 340B program, potentially leaving other covered entities vulnerable to delayed discounts. It could be seen as an incomplete solution to a systemic issue.
Estimated impact: This definition determines the exact scope of the bill's impact, affecting thousands of specific healthcare facilities across the country and their relationships with drug manufacturers.